iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meeting
Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on September 16–20, 2022 in Milan, Italy. A summary of the presentations and posters is included below.
Key Glaucoma Presentations: Papers
David Lubeck, MD (USA)
Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty in Patients With Mild–Moderate Glaucoma as Compared to Severe Glaucoma
Session: Minimally Invasive Glaucoma Surgery
Date: Sunday, September 18, 2022
Time: 2:00-3:30pm
Room: Red 1-2 – Podium 4
Norbert Koerber, FEBO (Germany)
5-Year Clinical Effectiveness of Ab-Interno Canaloplasty in Reducing the Medication Burden in Glaucoma Patients
Session: What is New in Glaucoma
Date: Sunday, September 18, 2022
Time: 2:15-3:45pm
Room: Podium 3
Type: Presented Poster
Mahmoud Khaimi, MD (USA)
Ab-Interno Canaloplasty Standalone Versus Combined With Cataract Surgery—36-Month Outcomes in +1000 Eyes
Session: Glaucoma and Combined Cataract
Date: Monday, September 19, 2022
Time: 10:00-11:30am
Room: Red 1-2 – Podium 4
Mahmoud Khaimi, MD (USA)
Ab-Interno Canaloplasty in Patients With Primary Angle Closure—12-Month Outcomes
Session: Glaucoma and Combined Cataract
Date: Monday, September 19 2022
Time: 10:00-11:30am
Room: Red 1-2 – Podium 4
Key Glaucoma Presentations: Posters
Javier Urcola, MD (Spain)
Ab-Externo Canaloplasty With And Without Suture In Highly Myopic Eyes
Date: Friday, September 16, 2022
Maya Mueller, MD (Switzerland)
Canaloplasty Ab Interno (ABiC)—3-Year Results Of A Novel Minimally Invasive Glaucoma Surgery (MIGS) Technique
Date: Friday, September 16, 2022
Nathan Kerr, MD (Australia)
iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma
Date: Friday, September 16, 2022
David Lubeck, MD (USA)
24-Month Evaluation of Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty
Date: Friday, September 16, 2022
Norbert Koerber, FEBO (Germany)
5-Year Clinical Effectiveness of Ab-Interno Canaloplasty in Controlled and Uncontrolled Glaucoma Patients
Date: Friday, September 16, 2022
Full session details can be accessed via the ESCRS program:
https://escrs-program.m-anage.com/escrs2022/en-GB/PublicProgram/Index?pProgram
“Canaloplasty has traditionally been performed by glaucoma surgeons in patients with late-stage disease. Today, canaloplasty is routinely used earlier in the treatment paradigm, and often in combination with cataract surgery. To that end, the ESCRS provides an important opportunity to connect with my European peers across the disciplines of cataract, glaucoma, and general ophthalmology to discuss how canaloplasty can best be deployed in the management of patients with glaucoma,” said Dr. Mahmoud A. Khaimi, chief medical consultant with Nova Eye Medical.
Nova Eye Medical will also be exhibiting at the ESCRS in exhibit X-11, X-13, and X-15.